aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development PlatformGlobeNewsWire • 03/24/20
aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public OfferingGlobeNewsWire • 03/10/20
aTyr Pharma Announces Publication in the Journal Cellular and Molecular ImmunologyGlobeNewsWire • 02/27/20
aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in JapanGlobeNewsWire • 01/06/20
aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923GlobeNewsWire • 12/12/19
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/15/19
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/15/19
aTyr Pharma's (LIFE) CEO Sanjay Shukla on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/14/19
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/26/19